Hainan Huluwa Pharmaceutical Group (605199.SH) has been granted approval to conduct clinical trials for pediatric pulmonary heat cough and asthma granules.
ST Huluo Wa (605199.SH) announced that the company has recently received approval from the National Medical Products Administration regarding...
Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the company has recently received the Drug Clinical Trial Approval Notification issued by the National Medical Products Administration regarding the Children's Pulmonary Heat Cough and Asthma Granules. This allows the product to carry out clinical trials for the treatment of pediatric influenza.
Related Articles
EDIANYUN (02416) spent HK$583,500 to repurchase 260,000 shares on September 15th.
HSBC Holdings (00005) will distribute a second interim dividend for 2025 of $0.1 per share on September 26th.
ALI HEALTH (00241) awarded a total of 949,000 restricted stock units.
EDIANYUN (02416) spent HK$583,500 to repurchase 260,000 shares on September 15th.
HSBC Holdings (00005) will distribute a second interim dividend for 2025 of $0.1 per share on September 26th.
ALI HEALTH (00241) awarded a total of 949,000 restricted stock units.
